Nordic Life Science 1
Business deals – Acquisitions – Agreements – Coll
aborations T E X T B Y M AL IN O T M ANI IN F R A S T RUC T UR E New laboratory building inaugurated at Medicon Village The building is the largest investment in laboratory capacity in Skåne for many years. M A NUF A C T UR I NG Finport has opened in Kuopio FinVector’s new production unit is set to become one of the world’s largest facilities for manufacturing gene-therapy treatments. THE FACILITY PRODUCES the viral vectorbased active pharmaceutical ingredient in Adstiladrin, the only non-replicating gene therapy for high-risk non-muscle invasive bladder cancer that has been approved by the FDA. FinVector is part of the international company Ferring Ventures, and since 2014 the Ferring Group has invested over EUR 600 million in the development of this treatment, of which more than half has been in Finland and Kuopio. “The development of our Finport facility, a state-of-the-art manufacturing site [four-story, 25,000 m2 ], is a key highlight. It not only creates high-quality jobs and brings skilled talent and taxpayer money to Kuopio, but also positions the city as a hub for health tech innovation and a growing ecosystem in Finland,” says Matthias Krieger, Managing Director, FinVector. FinVector is one of the largest private-sector employers in and around Kuopio, having more than doubled its staff to around 500 in the past 30 months. NLS THIS INVESTMENT in 12,500 square meters of space distributed across four levels, puts us in a strong position for continued expansion in the coming years, states Medicon Village. “The new laboratory building enhances the image of Lund as a research and university city, and helps to position Medicon Village as the natural node for life science in southern Sweden. The investment is also significant from an Öresund perspective as we see great potential in attracting more Danish companies to Skåne. A stronger exchange of research across the strait is important for the region’s competitiveness,” says Petter Hartman, CEO, Medicon Village Innovation AB. NLS SWEDEN Thermo Fisher Scientific opens bioanalytical laboratory in Gothenburg A NEW LABORATORY, creating up to 140 new jobs for researchers and laboratory staff, will be established during the last quarter of 2025. The PPD clinical research business of Thermo Fisher Scientific will expand its lab footprint in Europe, with a new lab in Gothenburg located in GoCo Health Innovation City, just south of AstraZeneca’s R&D facility. It will be 2,700 square meters in size. “We are delighted that this major employer will establish a large-scale facility in the Gothenburg region, creating knowledgeintensive jobs in our growing life science sector. The fact that Thermo Fisher Scientific has chosen Gothenburg for its European expansion is a sign of strength for us as a region,” says Patrik Andersson, CEO, Business Region Göteborg. NLS Mats Paulsson, founder of the Mats Paulsson Foundations, together with Mats Persson, Sweden's Minister for Employment and Integration NORDICLIFESCIENCE.ORG | 9